1
|
Petit C, Saillard C, Mohty B, Hicheri Y, Villetard F, Maisano V, Charbonnier A, Rey J, D'Incan E, Rouzaud C, Gelsi-Boyer V, Murati A, Lhoumeau AC, Ittel A, Mozziconacci MJ, Alary AS, Hospital MA, Vey N, Garciaz S. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients. Eur J Haematol 2024; 112:530-537. [PMID: 38031389 DOI: 10.1111/ejh.14140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 11/09/2023] [Accepted: 11/10/2023] [Indexed: 12/01/2023]
Abstract
OBJECTIVES To compare the efficacy of venetoclax-azacitidine (VEN-AZA) with AZA in the real-life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML). METHODS We retrospectively analysed R/R AML patients treated with VEN-AZA at the Institut Paoli Calmettes between September 2020 and February 2022. We compared them to a historical cohort of patients treated with AZA between 2010 and 2021. RESULTS Thirty-five patients treated with VEN-AZA were compared with 140 patients treated with AZA. There were more favourable cytogenetics (25.7% vs. 8.6%; p = 0.01) and less FLT3-ITD mutated AML (8.8% vs. 25.5%; p = .049) in the VEN-AZA group. The overall 30-day mortality rate was 7.4% and the overall 90-day mortality was 20%, with no difference between the groups. The complete remission rate was 48.6% in the VEN-AZA group versus 15% (p < .0001). The composite complete response rate was 65.7% in the VEN-AZA group versus 23.6% (p < .0001). OS was 12.8 months in the VEN-AZA group versus 7.3 months (p = 0.059). Patients with primary refractory AML, poor-risk cytogenetics, prior hematopoietic stem-cell transplantation (HSCT) and FLT3-ITD mutated AML had lower response and survival rates. CONCLUSION VEN-AZA was associated with a better response rate and a longer survival than AZA monotherapy in AML patients who relapsed after or were refractory to intensive chemotherapy.
Collapse
Affiliation(s)
- C Petit
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - C Saillard
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - B Mohty
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - Y Hicheri
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - F Villetard
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - V Maisano
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - A Charbonnier
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - J Rey
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - E D'Incan
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - C Rouzaud
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - V Gelsi-Boyer
- Département de Biologie des Tumeurs CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France
| | - A Murati
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - A C Lhoumeau
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - A Ittel
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - M J Mozziconacci
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - A S Alary
- Département de Biologie des Tumeurs, Institut Paoli-Calmettes, Marseille, France
| | - M-A Hospital
- Département d'hématologie, Institut Paoli-Calmettes, Marseille, France
| | - N Vey
- Département d'hématologie, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France
| | - S Garciaz
- Département d'hématologie, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Marseille, France
| |
Collapse
|
2
|
Riecke K, Müller V, Neunhöffer T, Park-Simon TW, Weide R, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Wuerstlein R, Denkert C, Decker T, Fehm T, Nekljudova V, Rey J, Loibl S, Laakmann E, Witzel I. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry. ESMO Open 2023; 8:101213. [PMID: 37075697 DOI: 10.1016/j.esmoop.2023.101213] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 02/26/2023] [Accepted: 03/10/2023] [Indexed: 04/21/2023] Open
Abstract
BACKGROUND Up to 30% of metastatic breast cancer (BC) patients develop brain metastases (BM). Prognosis of patients with BM is poor and long-term survival is rare. Identification of factors associated with long-term survival is important for improving treatment modalities. PATIENTS AND METHODS A total of 2889 patients of the national registry for BM in BC (BMBC) were available for this analysis. Long-term survival was defined as overall survival (OS) in the upper third of the failure curve resulting in a cut-off of 15 months. A total of 887 patients were categorized as long-term survivors. RESULTS Long-term survivors compared to other patients were younger at BC and BM diagnosis (median 48 versus 54 years and 53 versus 59 years), more often had HER2-positive tumors (59.1% versus 36.3%), less frequently luminal-like (29.1% versus 35.7%) or triple-negative breast cancer (TNBC) (11.9% versus 28.1%), showed better Eastern Cooperative Oncology Group (ECOG) performance status (PS) at the time of BM diagnosis (ECOG 0-1, 76.9% versus 51.0%), higher pathological complete remission rates after neoadjuvant chemotherapy (21.6% versus 13.7%) and lower number of BM (n = 1, BM 40.9% versus 25.4%; n = 2-3, BM 26.5% versus 26.7%; n ≥4, BM 32.6% versus 47.9%) (P < 0.001). Long-term survivors had leptomeningeal metastases (10.4% versus 17.5%) and extracranial metastases (ECM, 73.6% versus 82.5%) less frequently, and asymptomatic BM more often at the time of BM diagnosis (26.5% versus 20.1%), (P < 0.001). Median OS in long-term survivors was about two times higher than the cut-off of 15 months: 30.9 months [interquartile range (IQR) 30.3] overall, 33.9 months (IQR 37.1) in HER2-positive, 26.9 months (IQR 22.0) in luminal-like and 26.5 months (IQR 18.2) in TNBC patients. CONCLUSIONS In our analysis, long-term survival of BC patients with BM was associated with better ECOG PS, younger age, HER2-positive subtype, lower number of BM and less extended visceral metastases. Patients with these clinical features might be more eligible for extended local brain and systemic treatment.
Collapse
Affiliation(s)
- K Riecke
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - V Müller
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Neunhöffer
- Frauenärzte am Dom, Mainz, Germany; HELIOS Dr. Horst Schmidt Clinic Wiesbaden, Wiesbaden, Germany
| | - T-W Park-Simon
- Hanover Medical School (MHH University), Hanover, Germany
| | - R Weide
- Institute for Health Services Research in Oncology, Koblenz, Germany
| | - A Polasik
- Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
| | - M Schmidt
- The University Medical Center Mainz, Mainz, Germany
| | - J Puppe
- Department of Obstetrics & Gynecology, University Hospital of Cologne, Cologne, Germany
| | - C Mundhenke
- Klinikum Bayreuth GmbH/Medizincampus Oberfranken, Bayreuth, Germany; Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nürnberg, Erlangen, Germany
| | - K Lübbe
- Diakovere Henriettenstift, Breast Center, Hannover, Germany
| | - T Hesse
- Agaplesion Diakonieklinikum Rotenburg, Rotenburg, Germany
| | - M Thill
- Department of Gynecology and Gyneacological Oncology, Agaplesion Markus Hospital, Frankfurt, Germany
| | - R Wuerstlein
- Department of Obstetrics and Gynecology, Breast Center and CCC Munich, LMU University Hospital, Munich, Germany
| | - C Denkert
- Institute of Pathology, Philipps University Marburg and University Hospital Marburg (UKGM), Marburg, Germany
| | - T Decker
- Onkology, Haematology Ravensburg, Ravensburg, Germany
| | - T Fehm
- Universitätsklinikum Düsseldorf, Düsseldorf, Germany
| | | | - J Rey
- GBG Forschungs GmbH, Neu-Isenburg, Germany
| | - S Loibl
- GBG Forschungs GmbH, Neu-Isenburg, Germany
| | - E Laakmann
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - I Witzel
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Gynecology, University Hospital Zurich, Zürich, Switzerland.
| |
Collapse
|
3
|
Laakmann E, Riecke K, Neunhöffer T, Park-Simon TW, Weide R, Polasik A, Schmidt M, Puppe J, Fasching P, Hesse T, Decker T, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Mueller V, Witzel I. 269P Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Galas K, Gleitsmann M, Rey J, Solbach C, Witzel I, Seliger B, Karn T, Schmatloch S, Schneeweiss A, Sinn B, Fehm T, Denkert C, Litmeyer AS, Jank P, Furlanetto J, Ortmann O, Van Mackelenbergh M, Nekljudova V, Loibl S. 151P Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
5
|
Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, Zahm DM, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching PA, Nekljudova V, Denkert C, Untch M. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022; 33:1149-1158. [PMID: 35961599 DOI: 10.1016/j.annonc.2022.07.1940] [Citation(s) in RCA: 69] [Impact Index Per Article: 34.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 06/22/2022] [Accepted: 07/27/2022] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Addition of immune checkpoint inhibitors (CPI) to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo (NCT02685059) trial, addition of durvalumab to NACT as previously reported led to a moderate increase in pCR rate by absolute 9% (p=0.287). PATIENTS AND METHODS Durvalumab or placebo 1.5g/placebo q4 weeks plus nab-paclitaxel 125mg/m2 weekly for 12 weeks, followed by 4 cycles durvalumab/placebo plus epirubicin/cyclophosphamide (EC) q2 weeks was given to cT1b-cT4a-d TNBC patients. Durvalumab was not continued after surgery. Primary objective was pathological complete response (pCR). Secondary endpoints included invasive disease-free survival (iDFS), distant disease-free survival (DDFS) and overall survival (OS). RESULTS 174 patients were randomised between June 2016 and October 2017. After a median follow-up of 43.7 months, 34 events had occurred. Despite a non-significant increase in the pCR rate, significant differences were observed for 3-year iDFS, DDFS and OS: iDFS was 85.6% with durvalumab vs 77.2% with placebo (HR 0.48, 95%CI 0.24-0.97, stratified log-rank p=0.036); DDFS 91.7% vs 78.4% (HR 0.31, 95%CI 0.13-0.74, p=0.005); OS 95.2% vs 83.5% (HR 0.24, 95%CI 0.08-0.72, p=0.006). pCR patients had 3-year iDFS of 95.5% with durvalumab and 86.1% without (HR 0.22, 95% CI 0.05-1.06). In non-pCR cohort 3-year iDFS was 76.3% vs 69.7% (HR 0.67, 95% CI 0.29-1.54). Multivariable analysis confirmed durvalumab effect independent of the pCR effect. No new safety signals occurred. CONCLUSION Durvalumab added to NACT in TNBC significantly improved survival despite a modest pCR increase and no adjuvant component of durvalumab. Additional studies are needed to clarify the optimal duration and sequence of CPIs in the treatment of early TNBC.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg, Germany; Center for Hematology and Oncology Bethanien, Frankfurt, Germany.
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
| | - J Huober
- Universitätsklinikum Ulm, Germany; Breast Center, Cantonal hospital St Gallen, Switzerland
| | - M Braun
- Department of Gynecology, Breast Center, Red Cross Hospital Munich, Germany
| | - J Rey
- German Breast Group, Neu-Isenburg, Germany
| | - J-U Blohmer
- Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Germany
| | | | - D-M Zahm
- SRH Waldklinikum Gera GmbH, Germany
| | - C Hanusch
- Department of Gynecology, Breast Center, Red Cross Hospital Munich, Germany
| | - J Thomalla
- Praxis für Hämatologie und Onkologie Koblenz, Germany
| | | | - P Staib
- Klinik für Hämatologie und Onkologie, St.-Antonius Hospital, Eschweiler, Germany
| | - T Link
- Department of Gynecology and Obstetrics, Technische Universität Dresden, Dresden, Germany
| | - K Rhiem
- Center for Hereditary Breast and Ovarian Cancer and Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Germany
| | - C Solbach
- Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Frankfurt, Germany
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-Nuremberg, National Center for Tumour Diseases, Erlangen, Germany
| | | | - C Denkert
- Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany
| | - M Untch
- HELIOS Klinikum Berlin Buch, Berlin, Germany
| | | |
Collapse
|
6
|
Laakmann E, Witzel I, Neunhöffer T, Park-Simon TW, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm DM, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open 2022; 7:100495. [PMID: 35653983 PMCID: PMC9271494 DOI: 10.1016/j.esmoop.2022.100495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Revised: 04/13/2022] [Accepted: 04/14/2022] [Indexed: 11/24/2022] Open
Abstract
Background Up to 40% of patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer develop brain metastases (BMs). Understanding of clinical features of these patients with HER2-positive breast cancer and BMs is vital. Patients and methods A total of 2948 patients from the Brain Metastases in Breast Cancer registry were available for this analysis, of whom 1311 had primary tumors with the HER2-positive subtype. Results Patients with HER2-positive breast cancer and BMs were—when compared with HER2-negative patients—slightly younger at the time of breast cancer and BM diagnosis, had a higher pathologic complete response rate after neoadjuvant chemotherapy and a higher tumor grade. Furthermore, extracranial metastases at the time of BM diagnosis were less common in HER2-positive patients, when compared with HER2-negative patients. HER2-positive patients had more often BMs in the posterior fossa, but less commonly leptomeningeal metastases. The median overall survival (OS) in all HER2-positive patients was 13.2 months (95% confidence interval 11.4-14.4). The following factors were associated with shorter OS (multivariate analysis): older age at BM diagnosis [≥60 versus <60 years: hazard ratio (HR) 1.63, P < 0.001], lower Eastern Cooperative Oncology Group status (2-4 versus 0-1: HR 1.59, P < 0.001), higher number of BMs (2-3 versus 1: HR 1.30, P = 0.082; ≥4 versus 1: HR 1.51, P = 0.004; global P = 0.015), BMs in the fossa anterior (HR 1.71, P < 0.001), leptomeningeal metastases (HR 1.63, P = 0.012), symptomatic BMs at diagnosis (HR 1.35, P = 0.033) and extracranial metastases at diagnosis of BMs (HR 1.43, P = 0.020). The application of targeted therapy after the BM diagnosis (HR 0.62, P < 0.001) was associated with longer OS. HER2-positive/hormone receptor-positive patients showed longer OS than HER2-positive/hormone receptor-negative patients (median 14.3 versus 10.9 months; HR 0.86, P = 0.03), but no differences in progression-free survival were seen between both groups. Conclusions We identified factors associated with the prognosis of HER2-positive patients with BMs. Further research is needed to understand the factors determining the longer survival of HER2-positive/hormone receptor-positive patients. Patients with HER2-positive BMs from breast cancer have the best prognosis compared with other tumor subtypes. Among HER2-positive patients, hormone receptor-positive patients have the longest survival. HER2-targeted therapy is significantly associated with a better prognosis in patients with BMs. On average, two HER2-targeted therapy lines were administered prior to the development of BMs. New compounds are urgently needed to improve the outcome of this subgroup of patients.
Collapse
Affiliation(s)
- E Laakmann
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - I Witzel
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - T Neunhöffer
- Frauenärzte am Dom, Mainz, HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany
| | | | - R Weide
- Institut für Versorgungsforschung in der Onkologie, Koblenz, Germany
| | - K Riecke
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Polasik
- Universitätsklinikum Ulm, Ulm, Germany
| | - M Schmidt
- Universitätsmedizin Mainz, Mainz, Germany
| | - J Puppe
- Universitätsfrauenklinik Köln, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Köln, Germany
| | - C Mundhenke
- Frauenklinik, Klinikum Bayreuth, Bayreuth, Germany
| | - K Lübbe
- Diakovere Henriettenstift, Breast Center, Hannover, Germany
| | - T Hesse
- Agaplesion Diakonieklinikum Rotenburg, Rotenburg, Germany
| | - M Thill
- Agaplesion Markus Krankenhaus, Frankfurt, Germany
| | - D-M Zahm
- Department of Gynecology, SRH Wald-Klinikum Gera GmbH, Gera, Germany
| | - C Denkert
- Institut für Pathologie UKGM - Universitätsklinikum Marburg, Marburg, Germany
| | - T Fehm
- Universitätsklinikum Düsseldorf, Düsseldorf, Germany
| | | | - J Rey
- GBG Forschungs GmbH, Germany
| | - S Loibl
- GBG Forschungs GmbH, Germany
| | - V Müller
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| |
Collapse
|
7
|
Riecke K, Laakmann E, Neunhöffer T, Park-Simon TW, Weide R, Schmidt M, Polasik A, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm DM, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V, Witzel I. 170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
8
|
Marmé F, Hanusch C, Furlanetto J, Denkert C, Link T, Untch M, Blohmer JU, Jackisch C, Reinisch M, Rhiem K, Schneeweiss A, Solbach C, Schöllhorn L, Fasching P, Rey J, Loibl S. 199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
9
|
Laakmann E, Witzel I, Neunhöffer T, Park-Simon TW, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill M, Zahm DM, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Mueller V. 95MO Characteristics of patients with brain metastases from HER2-positive breast cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.03.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
10
|
Špadina M, Dourdain S, Rey J, Bohinc K, Pellet-Rostaing S, Dufrêche JF, Zemb T. How acidity rules synergism and antagonism in liquid–liquid extraction by lipophilic extractants—Part II: application of the ienaic modelling. Solvent Extraction and Ion Exchange 2021. [DOI: 10.1080/07366299.2021.1899614] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- M. Špadina
- ICSM, Univ Montpellier, CEA, CNRS, ENSCM, Marcoule, France
- Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia
| | - S. Dourdain
- ICSM, Univ Montpellier, CEA, CNRS, ENSCM, Marcoule, France
| | - J. Rey
- ICSM, Univ Montpellier, CEA, CNRS, ENSCM, Marcoule, France
| | - K. Bohinc
- Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia
| | | | | | - T. Zemb
- ICSM, Univ Montpellier, CEA, CNRS, ENSCM, Marcoule, France
| |
Collapse
|
11
|
Dourdain S, Špadina M, Rey J, Bohinc K, Pellet-Rostaing S, Dufrêche JF, Zemb T. How Acidity Rules Synergism and Antagonism in Liquid–Liquid Extraction by Lipophilic Extractants—Part I: Determination of Nanostructures and Free Energies of Transfer. Solvent Extraction and Ion Exchange 2021. [DOI: 10.1080/07366299.2021.1899606] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- S. Dourdain
- ICSM, Univ Montpellier, CEA, CNRS, ENSCM, Marcoule, France
| | - M. Špadina
- ICSM, Univ Montpellier, CEA, CNRS, ENSCM, Marcoule, France
- Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia
| | - J. Rey
- ICSM, Univ Montpellier, CEA, CNRS, ENSCM, Marcoule, France
| | - K. Bohinc
- Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia
| | | | | | - T. Zemb
- ICSM, Univ Montpellier, CEA, CNRS, ENSCM, Marcoule, France
| |
Collapse
|
12
|
Rodríguez M, Ruiz A, Piedra L, Gutierrez G, Rey J, Cruz M, Bisset J. Multiple insecticide resistance in Aedes aegypti (Diptera: Culicidae) from Boyeros municipality, Cuba and associated mechanisms. Acta Trop 2020; 212:105680. [PMID: 32866457 DOI: 10.1016/j.actatropica.2020.105680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 08/07/2020] [Accepted: 08/25/2020] [Indexed: 10/23/2022]
Abstract
In this study, insecticide resistance and the mechanisms responsible were characterized in Ae. aegypti of Boyeros municipality from Havana, Cuba. Boyeros represents a high epidemiological risk because it is located near the Havana International Airport, it is highly urbanized, and it has a large influx of people from endemic countries so that it qualifies as a sentinel site for surveillance. The larvae collected from five areas of this municipality showed resistance to temephos associated with metabolic enzymes. The adult mosquitoes displayed a deltamethrin resistance and less distinctly to other pyrethroids associated with a high frequency of sodium channel gene mutations (F1534C and V1016I), detected for the first time in a field population from Cuba. The presence in the field populations of two insecticide resistance mechanisms represents a limiting factor in the success of the control operations of this vector, so other strategies should be considered to preserve the effectiveness of the insecticides available in public health for vector control in Cuba.
Collapse
|
13
|
Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon T, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30567-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, Mudhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching PA, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. Charakteristika und Überlebensanalyse der Patienten mit asymptomatischen Hirnmetastasen eines Mammakarzinoms. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
| | - I Witzel
- Universitätsklinikum Hamburg-Eppendorf
| | | | - R Weide
- Institut für Versorgungsforschung in der Onkologie
| | - M Schmidt
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz
| | | | - V Möbus
- Universitätsklinikum Frankfurt
| | | | | | - K Lübbe
- Diakovere Henriettenstift, Breast Center
| | - T Hesse
- Agaplesion Diakonieklinikum Rotenburg
| | - K Riecke
- Universitätsklinikum Hamburg- Eppendorf
| | - M Thill
- Agaplesion Markus Krankenhaus
| | - PA Fasching
- Frauenklinik des Universitätsklinikums Erlangen
| | - C Denkert
- nstitut für Pathologie UKGM – Universitätsklinikum Marburg
| | - T Fehm
- Universitätsklinikum Düsseldorf
| | | | - J Rey
- German Breast Group, GBG Forschungs GmbH
| | - S Loibl
- German Breast Group, GBG Forschungs GmbH
| | - V Müller
- Universitätsklinikum Hamburg- Eppendorf
| |
Collapse
|
15
|
Riecke K, Mueller V, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, Polasik A, Hesse T, Lübbe K, Laakmann E, Thill M, Fasching P, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Witzel I. Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry – comparison of three different prognostic scores. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- K Riecke
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | - V Mueller
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | | | - R Weide
- Institut für Versorgungsforschung in der Onkologie
| | | | | | | | | | - T Hesse
- Agaplesion Diakonieklinikum Rotenburg
| | - K Lübbe
- Diakovere Henriettenstift, Breast Center
| | - E Laakmann
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| | - M Thill
- Agaplesion Markus Krankenhaus
| | | | - C Denkert
- Institut für Pathologie UKGM – Universitätsklinikum Marburg
| | - T Fehm
- Universitätsklinikum Düsseldorf
| | | | - J Rey
- German Breast Group, GBG Forschungs GmbH
| | - S Loibl
- German Breast Group, GBG Forschungs GmbH
| | - I Witzel
- Universitätklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
| |
Collapse
|
16
|
de Otálora XD, Ruiz R, Goiri I, Rey J, Atxaerandio R, San Martin D, Orive M, Iñarra B, Zufia J, Urkiza J, García-Rodríguez A. valorisation of spent coffee grounds as functional feed ingredient improves productive performance of Latxa dairy ewes. Anim Feed Sci Technol 2020. [DOI: 10.1016/j.anifeedsci.2020.114461] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Reinisch M, Untch M, Reimer T, Mahlberg R, Aydogdu M, Hitschold T, Jackisch C, Marmé F, Lück HJ, Ladda E, Schmatloch S, Schmidt M, Klare P, Sinn B, Stickeler E, Seiler S, Rey J, Klutinus N, Möbus V, Loibl S. 86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
18
|
Ohlendorf D, Salzer S, Haensel R, Rey J, Maltry L, Holzgreve F, Lampe J, Wanke EM, Groneberg DA. Influence of typical handball characteristics on upper body posture and postural control in male handball players. BMC Sports Sci Med Rehabil 2020; 12:4. [PMID: 32140229 PMCID: PMC7050121 DOI: 10.1186/s13102-020-0156-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Accepted: 01/03/2020] [Indexed: 11/10/2022]
Abstract
Background Well defined constitutional parameters support the physical fatigue resistance in handball to maintain the performance level for the majority of actions. Ideal constitutional conditions are necessary to achieve these physiological advantages in handball. But limited knowledge exists about the upper body posture or the postural control in correlation to the Body Mass Index (BMI), playing years, playing position and throwing arm in professional male handball. Methods Ninety-one male handball players participate (24.1 ± 5.9 years; playing experience 16.6 ± 5.7 years). A three-dimensional back scanner and a pressure measuring plate were used. Results Correlations between BMI and upper body posture and postural control were not significant. Same counts for the comparison between the left and right throwing arm according to upper body posture and postural control (p ≥ 0.05). Correlations between the years of playing can be found at pelvis height (p ≤ 0.04) and for the length of the Center of Pressure (CoP) (p ≤ 0.01). Wing players are 6.5-8.5 cm smaller. The playing position is independently of BMI, age or upper body posture (p ≥ 0.05). Backcourt players have a higher load of the left and a lower load of the right foot compared to wing players (p ≤ 0.001). Left-right comparison (p ≤ 0.001/ 0.01) can be seen in pivot player (covered area), backcourt player (weight distribution left/right [rear] foot), wing player (weight and force distribution left/right foot, covered area). Conclusion Goalkeeper, Backcourt and pivot players are taller and heavier than wing players. These physiological demands are not detectable in the upper body posture and slightly in postural control. Wing players have the most asymmetric load distribution and the longest length of CoP. Since goalkeepers do not differ from pivot or backcourt players, this can be lead back to the same training.
Collapse
Affiliation(s)
- D Ohlendorf
- 1Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - S Salzer
- 1Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - R Haensel
- 1Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - J Rey
- 2Institute of Biostatistics and Mathematical Modeling, Goethe-University, Frankfurt/Main, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany
| | - L Maltry
- 1Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - F Holzgreve
- 1Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - J Lampe
- 1Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - E M Wanke
- 1Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| | - D A Groneberg
- 1Institute of Occupational Medicine, Social Medicine and Environmental Medicine, Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
| |
Collapse
|
19
|
Quessard A, Cadier G, Imbault J, Rey J, Pernot M, Ouattara A. Assistance ventriculaire gauche par Impella® : indications, gestion et complications. Méd Intensive Réa 2019. [DOI: 10.3166/rea-2019-0093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
L’assistance monoventriculaire Impella® est une assistance microaxiale non pulsatile dépourvue de fonction d’oxygénation et/ou de décarboxylation. Sur le principe de la vis sans fin d’Archimède, elle aspire le sang dans le ventricule gauche pour le réinjecter dans la racine de l’aorte en regard des ostia coronaires. Selon le modèle utilisé, le débit d’assistance antérograde ainsi généré varie de 2,5 à 5 l/min. De par son mode de fonctionnement, l’assistance Impella® permet une décharge ventriculaire efficace. Ses indications sont l’angioplastie coronaire à haut risque et le choc cardiogénique réfractaire aux agents cardiovasoactifs. Chez le patient assisté par une extracorporeal life support (ECLS), la pompe Impella® permet de limiter le risque de surcharge ventriculaire. Chez le patient exclusivement assisté par Impella® soit d’emblée ou après une association avec l’ECLS, la voie d’abord axillaire permet sa réhabilitation active y compris la déambulation et l’activité physique. Elle se révèle alors une mise à l’épreuve cliniquement pertinente du ventricule droit en vue d’une assistance de longue durée de type left ventricular assist device.
Collapse
|
20
|
Silverio A, De Rosa R, Baldi C, Di Maio M, Prota C, Radano I, Herrmann E, Rey J, Citro R, Piscione F, Galasso G. P5098Percutaneous repair of functional mitral regurgitation in heart failure patients: a meta-analysis of 23 studies on mitraclip implantation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Silverio
- University of Salerno. Department of Medicine and Surgery, Salerno, Italy
| | - R De Rosa
- Chair of Cardiology, J.W. Goethe University Hospital of Frankfurt, Frankfurt, Germany
| | - C Baldi
- Department of Cardiology, A.O.U. “San Giovanni di Dio e Ruggi D'Aragona”, Salerno, Italy
| | - M Di Maio
- Division of Cardiology, Department of Cardiothoracic and Respiratory Sciences, University of Campania “Luigi Vanvitelli”, Monaldi Hospital, A.O.R.N. “Ospedali dei Colli”, Naples, Italy
| | - C Prota
- University of Salerno. Department of Medicine and Surgery, Salerno, Italy
| | - I Radano
- University of Salerno. Department of Medicine and Surgery, Salerno, Italy
| | - E Herrmann
- Department of Medicine, Institute of Biostatistics and Mathematical Modelling, Goethe University Frankfurt, Frankfurt, Germany
| | - J Rey
- Department of Medicine, Institute of Biostatistics and Mathematical Modelling, Goethe University Frankfurt, Frankfurt, Germany
| | - R Citro
- Department of Cardiology, A.O.U. “San Giovanni di Dio e Ruggi D'Aragona”, Salerno, Italy
| | - F Piscione
- University of Salerno. Department of Medicine and Surgery, Salerno, Italy
| | - G Galasso
- University of Salerno. Department of Medicine and Surgery, Salerno, Italy
| |
Collapse
|
21
|
Grüter B, Strange F, Täschler D, Rey J, von Gunten M, Grandgirard D, Leib S, Remonda L, Widmer H, Nevzati E, Fandino J, Marbacher S, Coluccia D. A Biodegradable Magnesium Stent for Aneurysm Healing in a Rat Sidewall Aneurysm Model. J Neurol Surg A Cent Eur Neurosurg 2018. [DOI: 10.1055/s-0038-1660694] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Affiliation(s)
- B. Grüter
- Kantonsspital Aarau, Aarau, Switzerland
| | | | | | - J. Rey
- Universität Bern, Bern, Switzerland
| | - M. von Gunten
- Institute of Pathology Laenggasse, Ittingen, Switzerland
| | - D. Grandgirard
- Neuroinfection Laboratory, Institute for Infectious Diseases, Bern, Switzerland
| | - S. Leib
- Neuroinfection Laboratory, Institute for Infectious Diseases, Bern, Switzerland
| | | | - H. Widmer
- Inselspital, Universitätsspital Bern, Bern, Switzerland
| | | | | | | | | |
Collapse
|
22
|
Varela E, Rey J, Plaza E, Muñoz de Propios P, Ortiz-Rodríguez JM, Álvarez M, Anel-López L, Anel L, De Paz P, Gil MC, Morrell JM, Ortega-Ferrusola C. How does the microbial load affect the quality of equine cool-stored semen? Theriogenology 2018; 114:212-220. [PMID: 29653389 DOI: 10.1016/j.theriogenology.2018.03.028] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Revised: 03/17/2018] [Accepted: 03/18/2018] [Indexed: 12/15/2022]
Abstract
Contaminating bacteria present in stallion ejaculates may compromise sperm quality during storage. Different procedures have been used to reduce the load of microorganisms in semen and avoid bacterial growth during storage. The aims of this study were: 1) to evaluate different techniques to eliminate bacteria in semen 2) to study the relationship between total microflora load (TML) and ROS production; and 3) to determine if TML affects the functionality of cool-stored sperm. Ejaculates from 11 stallions were split and processed in 3 ways: A. extended semen; B. conventional centrifuged semen, and C. Single layer centrifugation through Androcoll-E (SLC). All samples were preserved in INRA 96 at 5 °C for 72 h. Aliquots from native semen and from different treatments were taken for bacteriological analysis at T0, T24, T48 and T72h of storage and Total microbial load (TML: CFU (colony-forming units/ml) was calculated. The ROS production (dichlorodihydrofluorescein diacetate for H2O2, dihydroethidium for superoxide anion and CellROX deep red for total ROS), viability (YO-PRO-1-Ethidium) and lipid peroxidation (BODIPY-C11) were assessed by flow cytometry, and motility by CASA. The bacteria isolated were Corynebacterium spp, Arcanobacterium spp, Bacillus spp, Dermobacter, Staphylococcus spp, Streptococcus spp, Penicilium spp. TML of semen showed correlations with live sperm (r: -0.771), dead sperm (r: 0.580), H2O2 production (r: 0.740), and total ROS production (CellROX (+)) (r: -0.607), Total motility (r: 0.587), Progressive motility (r: -0.566), VCL (r: -0.664), VSL (r: -0,569), VAP (r: -0.534) (p ≤ 0.05). SLC removed 99.34% of the microbial load, which was assicated with a significanlty reduced H2O2 production (p ≤ 0.05). However, only samples treated with Androcoll-E had a higher total ROS production (CellROX +) (p ≤ 0.05). These results suggest that CellROX stain probably identifies superoxide production rather than H2O2 and this higher superoxide production may reflect an intense sperm functionality. The bacterial load increased the production of H2O2 in cool-stored semen which was associated with lower tolerance to refrigeration. SLC was the sperm processing technique that was most efficient at removing bacteria, reducing H2O2 production and selecting the most functional sperm.
Collapse
Affiliation(s)
- E Varela
- Unit of Infection Diseases, University of Extremadura, Caceres, Spain
| | - J Rey
- Unit of Infection Diseases, University of Extremadura, Caceres, Spain
| | - E Plaza
- Laboratory of Equine Reproduction and Equine Spermatology, University of Extremadura, Caceres, Spain
| | | | - J M Ortiz-Rodríguez
- Laboratory of Equine Reproduction and Equine Spermatology, University of Extremadura, Caceres, Spain
| | - M Álvarez
- Animal Reproduction and Obstetrics, University of León, León, Spain
| | - L Anel-López
- Animal Reproduction and Obstetrics, University of León, León, Spain
| | - L Anel
- Animal Reproduction and Obstetrics, University of León, León, Spain
| | - P De Paz
- Animal Reproduction and Obstetrics, University of León, León, Spain
| | - M C Gil
- Laboratory of Equine Reproduction and Equine Spermatology, University of Extremadura, Caceres, Spain
| | - J M Morrell
- Faculty of Veterinary Medicine and Animal Sciences, SLU, Uppsala, Sweden
| | | |
Collapse
|
23
|
Rey J, Fischer MS, Böttcher P. Sagittal joint instability in the cranial cruciate ligament insufficient canine stifle. Tierarztl Prax Ausg K 2018. [DOI: 10.1055/s-0038-1623760] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Summary
Objective: This in vivo study qualitatively describes the sagittal motion pattern of the cranial cruciate ligament (CrCL) insufficient canine stifle in operated and unoperated joints with cranio-caudal laxity on palpation. Material and methods: Sagittal stifle kinematics were recorded in vivo in dogs (> 15 kg BW) with unilateral (n = 7) or bilateral (n = 6) complete CrCL rupture and positive cranial drawer test as well as two sound control dogs using uniplanar fluoroscopic kinematography with the dogs walking on a treadmill. Stifle stability and sagittal motion pattern of the femur and the tibia were determined by visual inspection of the fluoroscopic video sequences. Results: Control dogs showed no cranio-caudal instability, identical to the contralateral stifles of the dogs with unilateral rupture. All unoperated stifles with CrCL rupture (n = 6) showed caudal slippage of the femur at the beginning of the stance phase. Of the 13 operated stifles (TightRope: n = 1, tibial tuberosity advancement, TTA: n = 6, tibial plateau leveling osteotomy, TPLO: n = 5, cranial closing wedge osteotomy, CCWO: n = 1) nine were unstable, showing the same motion pattern as the unoperated stifles. Conclusion: In the CrCL insufficient stifle with in vivo cranio-caudal instability caudal slippage of the distal femur at tow touch is the predominant motion pattern. Clinical significance: The discrepancy between in vivo motion pattern and in vitro simulation of CrCL insufficiency in which cranial tibial subluxation is the predominant sagittal motion pattern warrants further studies.
Collapse
|
24
|
Rey J, Bley M, Dufrêche JF, Gourdin S, Pellet-Rostaing S, Zemb T, Dourdain S. Thermodynamic Description of Synergy in Solvent Extraction: II Thermodynamic Balance of Driving Forces Implied in Synergistic Extraction. Langmuir 2017; 33:13168-13179. [PMID: 29059520 DOI: 10.1021/acs.langmuir.7b02068] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
In the second part of this study, we analyze the free energy of transfer in the case of synergistic solvent extraction. This free energy of the transfer of an ion in dynamic equilibrium between two coexisting phases is decomposed into four driving forces combining long-range interactions with the classical complexation free energy associated with the nearest neighbors. We demonstrate how the organometallic complexation is counterbalanced by the cost in free energy related to structural change on the colloidal scale in the solvent phase. These molecular forces of synergistic extraction are driven not only by the entropic term associated with the tight packing of electrolytes in the solvent and by the free energy cost of coextracting water toward the hydrophilic core of the reverse aggregates present but also by the entropic costs in the formation of the reverse aggregate and by the interfacial bending energy of the extractant molecules packed around the extracted species. Considering the sum of the terms, we can rationalize the synergy observed, which cannot be explained by classical extraction modeling. We show an industrial synergistic mixture combining an amide and a phosphate complexing site, where the most efficient/selective mixture is observed for a minimal bending energy and maximal complexation energy.
Collapse
Affiliation(s)
- J Rey
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule , Bat. 426, 30207 Bagnols sur Cèze, France
| | - M Bley
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule , Bat. 426, 30207 Bagnols sur Cèze, France
| | - J-F Dufrêche
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule , Bat. 426, 30207 Bagnols sur Cèze, France
| | - S Gourdin
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule , Bat. 426, 30207 Bagnols sur Cèze, France
| | - S Pellet-Rostaing
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule , Bat. 426, 30207 Bagnols sur Cèze, France
| | - T Zemb
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule , Bat. 426, 30207 Bagnols sur Cèze, France
| | - S Dourdain
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule , Bat. 426, 30207 Bagnols sur Cèze, France
| |
Collapse
|
25
|
Domínguez I, Luque R, Noriega M, Rey J, Alía J, Urda A, Marco F. Adult spinal deformity treated with minimally invasive surgery. Description of surgical technique, radiological results and literature review. Rev Esp Cir Ortop Traumatol (Engl Ed) 2017. [DOI: 10.1016/j.recote.2017.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
26
|
Rey J, Atak S, Dourdain S, Arrachart G, Berthon L, Pellet-Rostaing S. Synergistic Extraction of Rare Earth Elements from Phosphoric Acid Medium using a Mixture of Surfactant AOT and DEHCNPB. Solvent Extraction and Ion Exchange 2017. [DOI: 10.1080/07366299.2017.1362852] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- J. Rey
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat., Bagnols sur Cèze, France
| | - S. Atak
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat., Bagnols sur Cèze, France
| | - S. Dourdain
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat., Bagnols sur Cèze, France
| | - G. Arrachart
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat., Bagnols sur Cèze, France
| | - L. Berthon
- CEA, Nuclear Energy Division, RadioChemistry & Processes Department, Bagnols sur Cèze, France
| | - S. Pellet-Rostaing
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat., Bagnols sur Cèze, France
| |
Collapse
|
27
|
Büsching G, Rey J. P193 The introduction of step counters into a cardiopulmonary rehabilitation. A feasibility study with descriptive and statistical evaluation. Chest 2017. [DOI: 10.1016/j.chest.2017.04.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
28
|
Cismondi F, Rey J, von der Weth A, Kecskés S, Neuberger H, Ilic M, Bitz O, Boccaccini LV, Ihli T. Design Update and Mock-Up Test Strategy for the Validation of the EU-HCPB-TBM Concept. Fusion Science and Technology 2017. [DOI: 10.13182/fst09-a8906] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Cismondi
- Forschungszentrum Karlsruhe (FZK) Euratom Association, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - J. Rey
- Forschungszentrum Karlsruhe (FZK) Euratom Association, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - A. von der Weth
- Forschungszentrum Karlsruhe (FZK) Euratom Association, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - S. Kecskés
- Budapest University of Technology and Economics, 1111, Muegyetem rkp. 5-9, 1521 Budapest Pf. 91, Hungary
| | - H. Neuberger
- Forschungszentrum Karlsruhe (FZK) Euratom Association, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - M. Ilic
- Forschungszentrum Karlsruhe (FZK) Euratom Association, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - O. Bitz
- Forschungszentrum Karlsruhe (FZK) Euratom Association, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - L. V. Boccaccini
- Forschungszentrum Karlsruhe (FZK) Euratom Association, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - T. Ihli
- Forschungszentrum Karlsruhe (FZK) Euratom Association, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| |
Collapse
|
29
|
Meybohm P, Goehring M, Choorapoikayil S, Fischer D, Rey J, Herrmann E, Mueller M, Geisen C, Schmitz-Rixen T, Zacharowski K. Feasibility and efficiency of a preoperative anaemia walk-in clinic: secondary data from a prospective observational trial. Br J Anaesth 2017; 118:625-626. [DOI: 10.1093/bja/aex024] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
|
30
|
Weth AVD, Freiner P, Neuberger H, Rey J. Two Different Medium-Scale First Wall Fabrication Experiments at KIT for ITER Helium-Cooled Pebble Bed Test Blanket Module. Fusion Science and Technology 2017. [DOI: 10.13182/fst12-a14122] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. von der Weth
- Karlsruher Instut für Technologie, Institut für Neutronenphysik und Reaktortechnik Herrmann-von Helmholtzplatz 1, D-76344 Eggenstein-Leopoldshafen, Germany
| | - P. Freiner
- Karlsruher Instut für Technologie, Institut für Neutronenphysik und Reaktortechnik Herrmann-von Helmholtzplatz 1, D-76344 Eggenstein-Leopoldshafen, Germany
| | - H. Neuberger
- Karlsruher Instut für Technologie, Institut für Neutronenphysik und Reaktortechnik Herrmann-von Helmholtzplatz 1, D-76344 Eggenstein-Leopoldshafen, Germany
| | - J. Rey
- Karlsruher Instut für Technologie, Institut für Neutronenphysik und Reaktortechnik Herrmann-von Helmholtzplatz 1, D-76344 Eggenstein-Leopoldshafen, Germany
| |
Collapse
|
31
|
Rey J, Dourdain S, Dufrêche JF, Berthon L, Muller JM, Pellet-Rostaing S, Zemb T. Thermodynamic Description of Synergy in Solvent Extraction: I. Enthalpy of Mixing at the Origin of Synergistic Aggregation. Langmuir 2016; 32:13095-13105. [PMID: 27951687 DOI: 10.1021/acs.langmuir.6b02343] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Revisiting aggregation of extractant molecules into water-poor mixed reverse micelles, we propose in this paper to identify the thermodynamic origins of synergy in solvent extraction. Considering that synergistic extraction properties of a mixture of extractants is related to synergistic aggregation of this mixture, we identify here the elements at the origin of synergy by independently investigating the effect of water, acid, and extracted cations. Thermodynamic equations are proposed to describe synergistic aggregation in the peculiar case of synergistic solvent extraction by evaluating critical aggregation concentration (CAC) as well as specific interactions between extractants due to the presence of water, acid and cations. Distribution of two extractant molecules in the free extractants and in reverse micelles was assessed, leading to an estimation of the in-plane interaction parameter between extractants in the aggregates as introduced by Bergström and Eriksson ( Bergström, M.; Eriksson, J. C. A Theoretical Analysis of Synergistic Effects in Mixed Surfactant Systems . Langmuir 2000 , 16 , 7173 - 7181 ). Based on this model, we study the N,N'-dimethyl-N,N'-dioctylhexylethoxymalonamide (DMDOHEMA) and di(2-ethylexyl) phosphoric acid (HDEHP) mixture and show that adding nitric acid enhances synergistic aggregation at the equimolar ratio of the two extractants and that this configuration can be related to a favored enthalpy of mixing.
Collapse
Affiliation(s)
- J Rey
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| | - S Dourdain
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| | - J-F Dufrêche
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| | - L Berthon
- RadioChemistry & Processes Department, Nuclear Energy Division, CEA , 30207 Bagnols sur Cèze, France
| | - J M Muller
- RadioChemistry & Processes Department, Nuclear Energy Division, CEA , 30207 Bagnols sur Cèze, France
| | - S Pellet-Rostaing
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| | - T Zemb
- ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| |
Collapse
|
32
|
Pecheur O, Dourdain S, Guillaumont D, Rey J, Guilbaud P, Berthon L, Charbonnel M, Pellet-Rostaing S, Testard F. Synergism in a HDEHP/TOPO Liquid–Liquid Extraction System: An Intrinsic Ligands Property? J Phys Chem B 2016; 120:2814-23. [DOI: 10.1021/acs.jpcb.5b11693] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- O. Pecheur
- Nuclear Energy Division, RadioChemistry & Processes Department, CEA, 30207 Bagnols-sur-Cèze, France
| | - S. Dourdain
- ICSM, Institut de Chimie Séparative de Marcoule UMR 5257, 30207 Marcoule,
Bagnols-sur-Cèze, France
| | - D. Guillaumont
- Nuclear Energy Division, RadioChemistry & Processes Department, CEA, 30207 Bagnols-sur-Cèze, France
| | - J. Rey
- Nuclear Energy Division, RadioChemistry & Processes Department, CEA, 30207 Bagnols-sur-Cèze, France
| | - P. Guilbaud
- Nuclear Energy Division, RadioChemistry & Processes Department, CEA, 30207 Bagnols-sur-Cèze, France
| | - L. Berthon
- Nuclear Energy Division, RadioChemistry & Processes Department, CEA, 30207 Bagnols-sur-Cèze, France
| | - M.C. Charbonnel
- Nuclear Energy Division, RadioChemistry & Processes Department, CEA, 30207 Bagnols-sur-Cèze, France
| | - S. Pellet-Rostaing
- ICSM, Institut de Chimie Séparative de Marcoule UMR 5257, 30207 Marcoule,
Bagnols-sur-Cèze, France
| | - F. Testard
- LIONS,
NIMBE, CEA, CNRS, Université Paris-Saclay, CEA Saclay, 91191 Gif sur Yvette Cedex, France
| |
Collapse
|
33
|
Legros L, Girodon F, Lanotto JC, Rey J, Ugo V. Les mutations de la calréticuline, une nouvelle aide pour le diagnostic des syndromes myéloprolifératifs. Rev Med Interne 2015; 36:791-3. [DOI: 10.1016/j.revmed.2015.06.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2015] [Accepted: 06/06/2015] [Indexed: 10/23/2022]
|
34
|
Rey J, Encabo CM, Pizarro NE, San Martín JL, López-Timoneda F. [Management of difficult airway with inhalation induction in a patient with Lennox-Gastaut syndrome and neck injury]. Rev Esp Anestesiol Reanim 2015; 62:536-539. [PMID: 25687944 DOI: 10.1016/j.redar.2015.01.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2014] [Revised: 12/30/2014] [Accepted: 01/09/2015] [Indexed: 06/04/2023]
Abstract
Lennox-Gastaut syndrome is a childhood epileptic encephalopathy, and is characterized by frequent and difficult to treat seizures associated with mental retardation. The case is presented of a 21 year-old male with Lennox-Gastaut syndrome, with bilateral cervical facet joint dislocation fracture at C6-C7 and spinal canal compression as a result of a fall during a seizure. In this case the management of the difficult airway expected in an awake and uncooperative patient, with cervical spinal cord injury is described. An airway management strategy was proposed, that allowed a rapid and safe airway control with the best possible tolerance and maintaining the neck immobilised, so as not to increase neurological injury. Within this strategy, plan A was defined as inhalation induction with sevoflurane to maintain spontaneous breathing and tracheal intubation with Airtraq®. We believe that the Airtraq® video laryngoscope with inhalational induction with sevoflurane is a valid and effective alternative in the management of expected difficult airway.
Collapse
Affiliation(s)
- J Rey
- Servicio de Anestesiología y Reanimación, Hospital Clínico San Carlos, Madrid, España.
| | - C M Encabo
- Servicio de Anestesiología y Reanimación, Hospital Clínico San Carlos, Madrid, España
| | - N E Pizarro
- Servicio de Anestesiología y Reanimación, Hospital Clínico San Carlos, Madrid, España
| | - J L San Martín
- Servicio de Anestesiología y Reanimación, Hospital Clínico San Carlos, Madrid, España
| | - F López-Timoneda
- Servicio de Anestesiología y Reanimación, Hospital Clínico San Carlos, Madrid, España
| |
Collapse
|
35
|
Rey J, Dourdain S, Berthon L, Jestin J, Pellet-Rostaing S, Zemb T. Synergy in Extraction System Chemistry: Combining Configurational Entropy, Film Bending, and Perturbation of Complexation. Langmuir 2015; 31:7006-7015. [PMID: 26053416 DOI: 10.1021/acs.langmuir.5b01478] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Iron-uranium selectivity in liquid-liquid extraction depends not only on the mole fraction of extractants, but also on the nature of the diluent used, even if the diluent has no complexation interaction with the extracted ions. Modeling strong nonlinearity is difficult to parametrize without a large number of parameters, interpreted as "apparent constants". We determine in this paper the synergy curve versus mole fraction of HDEHP-TOPO (di(2-ethylexyl) phosphoric acid/tri-n-octyl phosphine oxide) and compare the free energy of aggregation to the free energy of extraction in various diluents. There is always a concomitant maximum of the two quantities, but with a gradual influence on intensity. The diluent is wetting the chains of the reverse aggregates responsible of the extraction. We show here that the intensity of the unexplained synergy peak is strongly dependent on the "penetrating" or "nonpenetrating" nature of the diluent. This experimental determination allows us to attribute the synergy to a combination of entropic effects favoring extraction, opposed to perturbation of the first coordination sphere by penetration as well as surfactant film bending energy.
Collapse
Affiliation(s)
- J Rey
- †ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| | - S Dourdain
- †ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| | | | - J Jestin
- §Laboratoire Léon Brillouin CEA/CNRS, CEA Saclay, 91191 Gif-sur-Yvette, France
| | - S Pellet-Rostaing
- †ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| | - T Zemb
- †ICSM/LTSM, CEA/CNRS/UM2/ENSCM UMR5257, Site de Marcoule, Bat. 426, 30207 Bagnols sur Cèze, France
| |
Collapse
|
36
|
Robles J, Cabello S, Quesada L, Ferrer J, Ibáñez S, Rey J, Uriol M, Barceló B, Gascó J. FP541INDOXYL SULFATE RELATED TO PROTEIN INTAKE AND INTRAHEMODIALYSIS ARTERIAL PRESSURE VARIATION, AND β2-MICROGLOBULIN TO ALBUMIN LEVELS AND INFLAMMATION. Nephrol Dial Transplant 2015. [DOI: 10.1093/ndt/gfv179.70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Blaise D, Saillard C, Fürst S, Faucher C, Prebet T, El Cheikh J, Castagna L, Charbonnier A, Granata A, Rey J, Devillier R, Mohty B, Arnoulet C, Moziconnaci M, Chabannon C, Vey N. 128 SINGLE CENTER EXPERIENCE OF RIC BASED ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 100 PATIENTS WITH MDS. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30129-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Launay-Vacher V, Aapro M, De Castro G, Cohen E, Deray G, Dooley M, Humphreys B, Lichtman S, Rey J, Scotté F, Wildiers H, Sprangers B. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 2015; 26:1677-84. [PMID: 25735315 DOI: 10.1093/annonc/mdv136] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Accepted: 02/19/2015] [Indexed: 12/11/2022] Open
Abstract
A number of cancer therapy agents are cleared by the kidney and may affect renal function, including cytotoxic chemotherapy agents, molecular targeted therapies, analgesics, antibiotics, radiopharmaceuticals and radiation therapy, and bone-targeted therapies. Many of these agents can be nephrotoxic, including targeted cancer therapies. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. Here, we review the renal effects associated with a selection of currenty approved targeted cancer therapies, directed to vascular endothelial growth factor or VEGF receptor(s) (VEGF/VEGFR), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor2 (HER2), BRAF, anaplastic lymphoma kinase (ALK), programmed cell death protein-1 or its ligand (PD-1/PDL-1), receptor activator of nuclear factor kappa-B ligand (RANKL), and mammalian target of rapamycin (mTOR). The early diagnosis and prompt treatment of these renal alterations are essential in the daily practice where molecular targeted therapies have a definitive role in the armamentarium used in many cancers.
Collapse
Affiliation(s)
- V Launay-Vacher
- Cancer & the Kidney International Network (C-KIN), Brussels Service ICAR, Pitié-Salpêtrière University Hospital, Paris
| | - M Aapro
- Cancer & the Kidney International Network (C-KIN), Brussels Multidisciplinary Oncology Institute, Genolier Clinic, Genolier, Switzerland
| | - G De Castro
- Cancer & the Kidney International Network (C-KIN), Brussels Department of Clinical Oncology, Sao Paulo State Cancer Institute, Sao Paulo, Brazil
| | - E Cohen
- Cancer & the Kidney International Network (C-KIN), Brussels Nephrology Section, Zablocki Veterans Affair Medical Center, Milwaukee, USA
| | - G Deray
- Cancer & the Kidney International Network (C-KIN), Brussels Department of Nephrology, Pitié-Salpêtrière University Hospital, Paris, France
| | - M Dooley
- Cancer & the Kidney International Network (C-KIN), Brussels Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, Australia
| | - B Humphreys
- Cancer & the Kidney International Network (C-KIN), Brussels Renal Division, Brigham and Women's Hospital, Boston
| | - S Lichtman
- Cancer & the Kidney International Network (C-KIN), Brussels Clinical Geriatrics Program, Memorial Sloan-Kettering Cancer Center, New-York, USA
| | - J Rey
- Cancer & the Kidney International Network (C-KIN), Brussels Department of Pharmacy, Jean Godinot Cancer Institute, Reims
| | - F Scotté
- Cancer & the Kidney International Network (C-KIN), Brussels Supportive Care in Cancer Unit, Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France
| | - H Wildiers
- Cancer & the Kidney International Network (C-KIN), Brussels Department of General Medicine, University Hospitals Leuven, Leuven
| | - B Sprangers
- Cancer & the Kidney International Network (C-KIN), Brussels Department of Nephrology, UZ Leuven, Leuven, Belgium
| |
Collapse
|
39
|
Rey J, Fernandez-Peralta L, Quintanilla LF, Hidalgo M, Presas C, Salmeron F, Puerto MA. Contrasting energy allocation strategies of two sympatric Merluccius species in an upwelling system. J Fish Biol 2015; 86:1078-1097. [PMID: 25641504 DOI: 10.1111/jfb.12619] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2014] [Accepted: 11/25/2014] [Indexed: 06/04/2023]
Abstract
This study investigated the somatic growth and energy allocation strategy of two sympatric hake species (Merluccius polli and Merluccius senegalensis), coexisting under the strong influence of the Mauritanian upwelling. The results revealed that ontogeny, bathymetry, geography and reproduction shaped the differences found between the condition dynamics of the two species. Aside from species-specific differences, individuals were observed in better condition in the northernmost area (more influenced by the permanent upwelling) and in the deepest waters, probably the most favourable habitat for Merluccius spp. Both species also displayed contrasting trade-offs in energy allocation probably due to the dissimilarity of their habitats, which favours the existence of divergent adaptive strategies in response to different ontogenic requirements. It was hypothesized that M. polli invests in mass and energy reserves while sacrificing growth, as larger sizes may not provide an ecological advantage in a deeper and more stable environment. Moreover, M. senegalensis capitalizes on a steady growth without major disruptions, enabling earlier spawning at the expense of a lower somatic mass, which is fitting to a less stable shallower environment. This study sheds new light on differences in the biological traits and life strategies of Merluccius spp., which permit their overlap in a complex upwelling system and may contribute to the long-lasting scientific-based management of these species.
Collapse
Affiliation(s)
- J Rey
- Instituto Español de Oceanografía, Centro Oceanográfico de Málaga, Muelle Pesquero s/n. 29640 Fuengirola, Spain
| | | | | | | | | | | | | |
Collapse
|
40
|
Sukhbaatar T, Dourdain S, Turgis R, Rey J, Arrachart G, Pellet-Rostaing S. Ionic liquids as diluents in solvent extraction: first evidence of supramolecular aggregation of a couple of extractant molecules. Chem Commun (Camb) 2015; 51:15960-3. [DOI: 10.1039/c5cc06422h] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Ionic liquids have many favorable properties over conventional diluents in solvent extraction.
Collapse
Affiliation(s)
- T. Sukhbaatar
- ICSM/LTSM
- CEA/CNRS/UM2/ENSCM UMR5257
- Site de Marcoule
- 30207 Bagnols sur Cèze
- France
| | - S. Dourdain
- ICSM/LTSM
- CEA/CNRS/UM2/ENSCM UMR5257
- Site de Marcoule
- 30207 Bagnols sur Cèze
- France
| | - R. Turgis
- ICSM/LTSM
- CEA/CNRS/UM2/ENSCM UMR5257
- Site de Marcoule
- 30207 Bagnols sur Cèze
- France
| | - J. Rey
- ICSM/LTSM
- CEA/CNRS/UM2/ENSCM UMR5257
- Site de Marcoule
- 30207 Bagnols sur Cèze
- France
| | - G. Arrachart
- ICSM/LTSM
- CEA/CNRS/UM2/ENSCM UMR5257
- Site de Marcoule
- 30207 Bagnols sur Cèze
- France
| | - S. Pellet-Rostaing
- ICSM/LTSM
- CEA/CNRS/UM2/ENSCM UMR5257
- Site de Marcoule
- 30207 Bagnols sur Cèze
- France
| |
Collapse
|
41
|
Launay-Vacher V, Janus N, Ray-Coquard I, Gligorov J, Selle F, Beuzeboc P, Daniel C, Spano J, Thery J, Goldwasser F, Mir O, Rey J, Jouannaud C, Morere J, Oudard S, Scotte F, Azizi M, Dorent R, Deray G. Hypertension, Proteinuria and Overall Survival in Elderly Cancer Patients Treated with Bevacizumab. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu356.69] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Rey J, Fischer MS, Böttcher P. Sagittal joint instability in the cranial cruciate ligament insufficient canine stifle. Caudal slippage of the femur and not cranial tibial subluxation. Tierarztl Prax Ausg K Kleintiere Heimtiere 2014; 42:151-156. [PMID: 24920141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Accepted: 01/13/2014] [Indexed: 06/03/2023]
Abstract
OBJECTIVE This in vivo study qualitatively describes the sagittal motion pattern of the cranial cruciate ligament (CrCL) insufficient canine stifle in operated and unoperated joints with cranio-caudal laxity on palpation. MATERIAL AND METHODS Sagittal stifle kinematics were recorded in vivo in dogs (> 15 kg BW) with unilateral (n = 7) or bilateral (n = 6) complete CrCL rupture and positive cranial drawer test as well as two sound control dogs using uniplanar fluoroscopic kinematography with the dogs walking on a treadmill. Stifle stability and sagittal motion pattern of the femur and the tibia were determined by visual inspection of the fluoroscopic video sequences. RESULTS Control dogs showed no cranio-caudal instability, identical to the contralateral stifles of the dogs with unilateral rupture. All unoperated stifles with CrCL rupture (n = 6) showed caudal slippage of the femur at the beginning of the stance phase. Of the 13 operated stifles (TightRope: n = 1, tibial tuberosity advancement, TTA: n = 6, tibial plateau leveling osteotomy, TPLO: n = 5, cranial closing wedge osteotomy, CCWO: n = 1) nine were unstable, showing the same motion pattern as the unoperated stifles. CONCLUSION In the CrCL insufficient stifle with in vivo cranio-caudal instability caudal slippage of the distal femur at tow touch is the predominant motion pattern. CLINICAL SIGNIFICANCE The discrepancy between in vivo motion pattern and in vitro simulation of CrCL insufficiency in which cranial tibial subluxation is the predominant sagittal motion pattern warrants further studies.
Collapse
Affiliation(s)
| | | | - P Böttcher
- Prof. Dr. Peter Böttcher, Klinik für Kleintiere, der Universität Leipzig, An den Tierkliniken 23, 04103 Leipzig, Germany,
| |
Collapse
|
43
|
Hoffman A, Rey J, Kiesslich R. Neue Techniken der modernen Endoskopie. Endo heute 2013; 26:208-215. [DOI: 10.1055/s-0033-1350357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
|
44
|
Lyonnet S, Rey F, Caillaud C, Abadie V, Munnich A, Rey J. Bases moléculaires de la phénylcétonurie en France : de l'invasion celte à la bataille de Poitiers. ACTA ACUST UNITED AC 2013. [DOI: 10.4267/10608/3878] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S, Moss S, Quirke P, Steele RJ, Vieth M, Aabakken L, Altenhofen L, Ancelle-Park R, Antoljak N, Anttila A, Armaroli P, Arrossi S, Austoker J, Banzi R, Bellisario C, Blom J, Brenner H, Bretthauer M, Camargo Cancela M, Costamagna G, Cuzick J, Dai M, Daniel J, Dekker E, Delicata N, Ducarroz S, Erfkamp H, Espinàs JA, Faivre J, Faulds Wood L, Flugelman A, Frkovic-Grazio S, Geller B, Giordano L, Grazzini G, Green J, Hamashima C, Herrmann C, Hewitson P, Hoff G, Holten I, Jover R, Kaminski MF, Kuipers EJ, Kurtinaitis J, Lambert R, Launoy G, Lee W, Leicester R, Leja M, Lieberman D, Lignini T, Lucas E, Lynge E, Mádai S, Marinho J, Maučec Zakotnik J, Minoli G, Monk C, Morais A, Muwonge R, Nadel M, Neamtiu L, Peris Tuser M, Pignone M, Pox C, Primic-Zakelj M, Psaila J, Rabeneck L, Ransohoff D, Rasmussen M, Regula J, Ren J, Rennert G, Rey J, Riddell RH, Risio M, Rodrigues V, Saito H, Sauvaget C, Scharpantgen A, Schmiegel W, Senore C, Siddiqi M, Sighoko D, Smith R, Smith S, Suchanek S, Suonio E, Tong W, Törnberg S, Van Cutsem E, Vignatelli L, Villain P, Voti L, Watanabe H, Watson J, Winawer S, Young G, Zaksas V, Zappa M, Valori R. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013; 45:51-9. [PMID: 23212726 PMCID: PMC4482205 DOI: 10.1055/s-0032-1325997] [Citation(s) in RCA: 186] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Population-based screening for early detection and treatment of colorectal cancer (CRC) and precursor lesions, using evidence-based methods, can be effective in populations with a significant burden of the disease provided the services are of high quality. Multidisciplinary, evidence-based guidelines for quality assurance in CRC screening and diagnosis have been developed by experts in a project co-financed by the European Union. The 450-page guidelines were published in book format by the European Commission in 2010. They include 10 chapters and over 250 recommendations, individually graded according to the strength of the recommendation and the supporting evidence. Adoption of the recommendations can improve and maintain the quality and effectiveness of an entire screening process, including identification and invitation of the target population, diagnosis and management of the disease and appropriate surveillance in people with detected lesions. To make the principles, recommendations and standards in the guidelines known to a wider professional and scientific community and to facilitate their use in the scientific literature, the original content is presented in journal format in an open-access Supplement of Endoscopy. The editors have prepared the present overview to inform readers of the comprehensive scope and content of the guidelines.
Collapse
Affiliation(s)
| | - L. von Karsa
- International Agency for Research on Cancer, Lyon, France
| | - J. Patnick
- NHS Cancer Screening Programmes Sheffield, United Kingdom,Oxford University Cancer Screening Research Unit, Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom
| | - N. Segnan
- International Agency for Research on Cancer, Lyon, France,CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - W. Atkin
- Imperial College London, London, United Kingdom
| | - S. Halloran
- Bowel Cancer Screening Southern Programme Hub, Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom,University of Surrey, Guildford, United Kingdom
| | | | - N. Malila
- Finnish Cancer Registry, Helsinki, Finland
| | - S. Minozzi
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - S. Moss
- The Institute of Cancer Research, Royal Cancer Hospital, Sutton, United Kingdom
| | - P. Quirke
- Leeds Institute of Molecular Medicine, St James’ University Hospital, Leeds, United Kingdom
| | - R. J. Steele
- Ninewells Hospital and Medical School, Dundee, United Kingdom
| | - M. Vieth
- Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany
| | - L. Aabakken
- Department of Medical Gastroenterology, Stavanger University Hospital, Stavanger, Norway
| | - L. Altenhofen
- Central Research Institute of Ambulatory Health Care, Berlin, Germany
| | | | - N. Antoljak
- Croatian National Institute of Public Health, Zagreb, Croatia,University of Zagreb School of Medicine, Zagreb, Croatia
| | - A. Anttila
- Finnish Cancer Registry, Helsinki, Finland
| | - P. Armaroli
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | | | - J. Austoker
- University of Oxford, Oxford, United Kingdom
| | - R. Banzi
- Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - C. Bellisario
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - J. Blom
- Karolinska Institutet, Stockholm, Sweden
| | - H. Brenner
- German Cancer Research Center, Heidelberg, Germany
| | - M. Bretthauer
- Institute of Health and Society, University of Oslo, Oslo, Norway
| | - M. Camargo Cancela
- National Cancer Registry, Cork, Ireland,Formerly International Agency for Research on Cancer, Lyon, France
| | | | - J. Cuzick
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, United Kingdom
| | - M. Dai
- Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China
| | - J. Daniel
- Formerly International Agency for Research on Cancer, Lyon, France,American Cancer Society, Atlanta, Georgia, United States of America
| | - E. Dekker
- Academic Medical Centre, Amsterdam, the Netherlands
| | - N. Delicata
- National Health Screening Services, Ministry of Health, Elderly & Community Care, Valletta, Malta
| | - S. Ducarroz
- International Agency for Research on Cancer, Lyon, France
| | - H. Erfkamp
- University of Applied Sciences FH Joanneum, Graz, Austria
| | - J. A. Espinàs
- Catalan Cancer Strategy, L’Hospitalet de Llobregat, Spain
| | - J. Faivre
- Digestive Cancer Registry of Burgundy, INSERM U866, University and CHU, Dijon, France
| | - L. Faulds Wood
- Lynn’s Bowel Cancer Campaign, Twickenham, United Kingdom
| | - A. Flugelman
- National Israeli Breast and Colorectal Cancer Detection, Haifa, Israel
| | - S. Frkovic-Grazio
- Department of Gynecological Pathology and Cytology, University Medical Center Ljubljana, Slovenia
| | - B. Geller
- University of Vermont, Burlington, Vermont, United States of America
| | - L. Giordano
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - G. Grazzini
- Cancer Prevention and Research Institute (ISPO), Florence, Italy
| | - J. Green
- University of Oxford, Oxford, United Kingdom
| | | | - C. Herrmann
- Formerly International Agency for Research on Cancer, Lyon, France,Cancer League of Eastern Switzerland, St. Gallen, Switzerland
| | - P. Hewitson
- University of Oxford, Oxford, United Kingdom
| | - G. Hoff
- Cancer Registry of Norway, Oslo, Norway,Telemark Hospital, Skien, Norway
| | - I. Holten
- Danish Cancer Society, Copenhagen, Denmark
| | - R. Jover
- Hospital General Universitario de Alicante, Alicante, Spain
| | - M. F. Kaminski
- Maria Sklodowska-Curie Memorial Cancer Centre and Medical Centre for Postgraduate Education, Warsaw, Poland
| | | | | | - R. Lambert
- International Agency for Research on Cancer, Lyon, France
| | - G. Launoy
- U1086 INSERM – UCBN, CHU Caen, France
| | - W. Lee
- The Catholic University of Korea College of Medicine, Seoul, Republic of Korea
| | | | - M. Leja
- University of Latvia, Riga, Latvia
| | - D. Lieberman
- Oregon Health & Science University, Portland, Oregon, United States of America
| | - T. Lignini
- International Agency for Research on Cancer, Lyon, France
| | - E. Lucas
- International Agency for Research on Cancer, Lyon, France
| | - E. Lynge
- University of Copenhagen, Copenhagen, Denmark
| | - S. Mádai
- MaMMa Healthcare Institute, Budapest, Hungary
| | - J. Marinho
- Health Administration Central Region Portugal, Aveiro, Portugal
| | | | - G. Minoli
- Gastroenterology Unit, Valduce Hospital, Como, Italy
| | - C. Monk
- GlaxoSmithKline Pharma Europe, London, United Kingdom
| | - A. Morais
- Regional Health Administration, Coimbra, Portugal
| | - R. Muwonge
- International Agency for Research on Cancer, Lyon, France
| | - M. Nadel
- Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - L. Neamtiu
- Prof. Dr Ion Chiricuţă, Cluj-Napoca, Romania
| | - M. Peris Tuser
- Catalan Institute of Oncology, L’Hospitalet de Llobregat, Spain
| | - M. Pignone
- University of North Carolina, Chapel Hill, North Carolina, United States of America
| | - C. Pox
- Ruhr Universität, Bochum, Germany
| | - M. Primic-Zakelj
- Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Slovenia
| | - J. Psaila
- National Health Screening Services, Ministry of Health, Elderly & Community Care, Valletta, Malta
| | - L. Rabeneck
- University of Toronto and Cancer Care Ontario, Toronto, Canada
| | - D. Ransohoff
- University of North Carolina, Chapel Hill, North Carolina, United States of America
| | - M. Rasmussen
- Bispebjerg University Hospital, Copenhagen, Denmark
| | - J. Regula
- Maria Sklodowska-Curie Memorial Cancer Centre and Medical Centre for Postgraduate Education, Warsaw, Poland
| | - J. Ren
- Formerly International Agency for Research on Cancer, Lyon, France
| | - G. Rennert
- National Israeli Breast and Colorectal Cancer Detection, Haifa, Israel
| | - J. Rey
- Institut Arnault Tzanck, St Laurent du Var, France
| | | | - M. Risio
- Institute for Cancer Research and Treatment, Candiolo-Torino, Italy
| | - V. Rodrigues
- Faculdade de Medicina – Universidade de Coimbra, Coimbra, Portugal
| | - H. Saito
- National Cancer Centre, Tokyo, Japan
| | - C. Sauvaget
- International Agency for Research on Cancer, Lyon, France
| | | | | | - C. Senore
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - M. Siddiqi
- Cancer Foundation of India, Kolkata, India
| | - D. Sighoko
- Formerly International Agency for Research on Cancer, Lyon, France,The University of Chicago, Department of Medicine, Hematology–Oncology Section, Center for Clinical Cancer Genetics, Global Health, Chicago, United States of America
| | - R. Smith
- American Cancer Society, Atlanta, Georgia, United States of America
| | - S. Smith
- University Hospitals Coventry & Warwickshire NHS Trust, Coventry, United Kingdom
| | - S. Suchanek
- Charles University and Military University Hospital, Prague, Czech Republic
| | - E. Suonio
- International Agency for Research on Cancer, Lyon, France
| | - W. Tong
- Chinese Academy of Medical Sciences, Beijing, China
| | - S. Törnberg
- Department of Cancer Screening, Stockholm Gotland Regional Cancer Centre, Stockholm, Sweden
| | | | - L. Vignatelli
- Agenzia Sanitaria e Sociale Regionale–Regione Emilia-Romagna, Bologna, Italy
| | - P. Villain
- University of Oxford, Oxford, United Kingdom
| | - L. Voti
- Formerly International Agency for Research on Cancer, Lyon, France,University of Miami, Miami, Florida, United States of America
| | | | - J. Watson
- University of Oxford, Oxford, United Kingdom
| | - S. Winawer
- Memorial Sloan–Kettering Cancer Center, New York, United States of America
| | - G. Young
- Gastrointestinal Services, Flinders University, Adelaide, Australia
| | - V. Zaksas
- State Patient Fund, Vilnius, Lithuania
| | - M. Zappa
- Cancer Prevention and Research Institute (ISPO), Florence, Italy
| | - R. Valori
- NHS Endoscopy, Leicester, United Kingdom
| |
Collapse
|
46
|
Bello M, Leone P, Nebreda P, Kusak M, Decampos J, Vaquero J, Sarasa J, Pestana A, Rey J. Molecular abnormalities of chromosome-19 in malignant gliomas - preferential involvement of the 19q13.2-q13.4 region. Int J Oncol 2012; 6:655-8. [PMID: 21556584 DOI: 10.3892/ijo.6.3.655] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A deletion mapping analysis of chromosome 19 was performed on a series of 101 samples derived from malignant gliomas. A total of 35 tumors displayed different deletions for the loci studied (D19S21, D19S11, D19S74, D19S7, D19S8, CKM, and D19S22). In most instances, losses involving the long arm markers of chromosome 19 were observed, and only four samples were characterized by losses on the short arm. No tumor was found displaying loss of both short and long arm markers. The higher frequency of deletions was detected in tumors with a major oligodendroglial component: 76% of samples included in this group displayed losses at 19q. Among the astrocytic tumors, the frequency of 19q alterations varied as follows: 11% in pilocytic astrocytomas, 17% in astrocytomas grade II, 10% in anaplastic astrocytomas and 21% in glioblastoma multiforme. No ependymoma was found displaying allele loss on chromosome 19. The common region of overlap for the 19q deletions observed involves primarily the distal portion of the long arm, 19q13.2-q13.4. In agreement with previous reports, these data suggest the non-random involvement of a tumor suppressor gene located at 19q13 in the genesis or progression of malignant gliomas.
Collapse
Affiliation(s)
- M Bello
- CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN. HOSP PRINCESA,DEPT NEUROSURG,MADRID,SPAIN. FDN JIMENEZ DIAZ,DEPT NEUROSURG,E-28040 MADRID,SPAIN. CLIN PUERTA HIERRO,DEPT NEUROSURG,MADRID,SPAIN. FDN JIMENEZ DIAZ,DEPT ANAT PATHOL,E-28040 MADRID,SPAIN
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Affiliation(s)
- G Fourcade
- Department of Neurology, Hospital Center of Narbonne, Narbonne, France.
| | | | | | | | | | | |
Collapse
|
48
|
Weth AVD, Freiner P, Neuberger H, Rey J. Two Different Medium-Scale First Wall Fabrication Experiments at KIT for ITER Helium-Cooled Pebble Bed Test Blanket Module. Fusion Sci Technol 2012. [DOI: 10.13182/fst11-453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
49
|
Neuberger H, von der Weth A, Rey J. KIT induced activities to support fabrication, assembly and qualification of technology for the HCPB-TBM. Fusion Engineering and Design 2011. [DOI: 10.1016/j.fusengdes.2011.03.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
50
|
Parent D, Rallet A, Jovenin N, Yazbek G, Cure H, Rey J. Tolerance of docetaxel: Is obesity a risk factor for toxicity? A pilot study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
248 Background: Few data are available in the literature regarding chemotherapy dosage adjustment in obese patients. Docetaxel is a lipophilic substance, highly bound to albumin; obesity might result in an accumulation and may lead to a higher rate of toxicity. The objective of this study was to assess the tolerance to docetaxel in obese and non obese patients, according to their body mass index (BMI). Methods: A retrospective study was performed. Patients were divided according to their BMI, considering a limit of 30 kg/m2. All patients received docetaxel (100 mg/m2) as a part of adjuvant chemotherapy for breast carcinoma. Toxicity of docetaxel such as neutropenia, hand-foot syndrome (HFS), mucositis, and neuropathy were assessed in both groups. The included patients received docetaxel alone or in association with trastuzumab or bevacizumab. Qualitative data analysis was performed using Fisher's exact test. Quantitative data were studied using the Student test. Results: Among the 49 patients, 18 (37%) presented with a BMI greater than 30 kg/m2. The median age was 53 years in the group BMI greater than 30 and 55 years in the group BMI less than 30 (p = 0.9383). The median value for albumin was 75 g/L (59-86 g/L) in the BMI greater than 30 and 71 g/L (56-79 g/L) in the BMI less than 30 (p = 0.122). Toxicity in both groups is shown in the table below. No neuropathy was observed. Conclusions: Obese patients (BMI > 30 kg/m2) presented with more toxicities (p = 0.013). Hypoalbuminemia did not represent a risk factor for toxicity in this study. Obesity is a risk factor for toxicity in patients treated with docetaxel. Dosage calculation according to body surface area is not suitable for these patients. Toxicity in the group BMI < 30 seems to demonstrate greater susceptibility to the molecule for these patients. Further studies will try to identify the different mechanisms of toxicity of docetaxel involved obese patients, including the interaction between docetaxel and fats. Measures have also to be taken to obtain a favorable effectiveness/toxicity balance in obese patients. [Table: see text]
Collapse
Affiliation(s)
- D. Parent
- Institut Jean-Godinot, Reims, France
| | - A. Rallet
- Institut Jean-Godinot, Reims, France
| | | | - G. Yazbek
- Institut Jean-Godinot, Reims, France
| | - H. Cure
- Institut Jean-Godinot, Reims, France
| | - J. Rey
- Institut Jean-Godinot, Reims, France
| |
Collapse
|